EWTX

39.9163.05%
KK

Kevin Koch

President, CEO & Director

Dr. Kevin Koch, Ph.D. is a Venture Partner at OrbiMed Advisors, LLC since 2016. He had been a Member of Scientific Advisory Board at OnKure Therapeutics, Inc. until December 2024. Dr. Koch serves as a Member of Scientific Advisory Board at Frontier Medicines Corporation since July 2021. Dr. Koch served as a Member of Advisors at HotSpot Therapeutics, Inc until, 2021. He has been the President and Chief Executive Officer of Edgewise Therapeutics since August 2017. Dr. Koch serves as Director of Edgewise Therapeutics, Inc. June 2017 and served as its Chief Financial Officer from August 2017 to September 2020. Prior to joining OrbiMed Advisors LLC, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to joining Biogen, Dr. Koch was a Co-Founder of Array Biopharma Inc. in February 1998 and served as its President, Chief Scientific Officer from May 1998 to November 2013 and was its Director from May 1998 to April 2012. Prior to Array, Dr. Koch held senior positions at Amgen Inc. and Pfizer Central Research. Prior to in Array, Dr. Koch served as an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to April 1998 for Amgen Inc. From September 1988 to May 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator, Senior Research Scientist and Project Coordinator for the Cellular Migration and Immunology Project Teams. Prior to acting as a consultant, Dr. Koch served as the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen, Inc. from December 2013 to September 2015, where he managed global drug discovery and biomarker development as well as the immunology and hematology teams. Dr. Koch is the Treasurer and Board Member of the Inflammation Research Association. Dr. Koch served a Director of miRagen Therapeutics, Inc. since February 2017. Prior to joining miRagen Therapeutics Board, he served as a Member of Private Miragen’s Board of Directors since July 2016. He is a Founding Board Member of Skyhawk Therapeutics; Inc. Dr. Koch serves on the boards of Neurogastrx Therapeutics. and Encycle Therapeutics and consults with several life science companies. Dr. Koch served as a Director of Array Biopharma, Inc, where he built a fully integrated R&D team that oversaw the invention of several clinical development candidates in the multiple therapeutic areas. from May 1998 to October 24, 2012. He is a Director of Skyhawk Therapeutics, Inc. He is a co-author or inventor of multiple patents and publications. He is Scientific Advisor at Terremoto Biosciences, Inc. and served as its Director. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York in 1983, Stony Brook and his Ph.D. in Synthetic Organic Chemistry from University of Rochester in 1988 and M.S in organic chemistry from University of Rochester in 1986. He previously served on the board of directors of Terremoto Biosciences from July 2021 to December 2023, both privately held biotechnology companies.

Positions